Dietary Supplement Manufacturing, Packaging, Labeling and Holding

Part 111 addresses manufacturing, packaging, labeling and holding operations for dietary supplements, with specific treatment of certain activities. A business’s role determines the applicable obligations. A distributor commissioning manufacture should not assume that a contract removes every responsibility relevant to its operations. Classification of the product as a dietary supplement must also be established. Part 111.

Specifications address components, in-process production and finished supplements as required by the rule. They concern identity, purity, strength, composition and relevant contamination limits. Testing or examination must be suitable to the specification and regulatory provision. A supplier certificate of analysis has conditions for reliance and is not an automatic substitute for every required verification. FDA compliance guide.

Quality-control personnel have defined review and approval responsibilities. Written procedures govern applicable operations, including equipment, laboratory controls, packaging and labeling. Controls must connect the approved formula and process with the batch actually produced. An inspection-ready binder is insufficient if production practice, equipment use or disposition decisions do not follow the documented controls. CGMP requirements.

A master manufacturing record is prepared for each unique formulation and batch size as required. The batch production record documents execution, relevant component identification, process steps, tests and quality-control disposition. These records serve different purposes and should remain linked. A corrected result or reprocessed batch requires the appropriate investigation and documented decision. FDA master-record explanation.

The rule includes provisions for product complaints, returned supplements and reserve samples, alongside relevant holding and distribution controls. Records must support identification and evaluation of affected products. A complaint alleging illness can also raise obligations outside Part 111. Manufacturing controls therefore need interfaces with labeling, postmarket information and the firm’s product-responsibility arrangements. Part 111.

Establish the operation’s role, map specifications to tests and quality-control decisions, then trace one batch through its records and distribution. Assess ingredient status and labeling under their separate legal provisions. New dietary ingredient notification and claim requirements are not satisfied by CGMP documentation alone. FDA’s supplement resources organize these distinct subjects. Industry resources · compliance guide.